S
2.77
0.16 (5.94%)
| Previous Close | 2.61 |
| Open | 2.58 |
| Volume | 230,715 |
| Avg. Volume (3M) | 923,586 |
| Market Cap | 474,526,560 |
| Price / Book | 2.20 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -0.430 |
| Total Debt/Equity (MRQ) | 13.46% |
| Current Ratio (MRQ) | 17.70 |
| Operating Cash Flow (TTM) | -81.41 M |
| Levered Free Cash Flow (TTM) | -47.87 M |
| Return on Assets (TTM) | -26.39% |
| Return on Equity (TTM) | -47.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Savara, Inc. | Bearish | Bullish |
AIStockmoo Score
2.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 2.75 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 98.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2024 | 24,471,264 |
| Vestal Point Capital, Lp | 31 Dec 2024 | 10,775,000 |
| Deerfield Management Company, L.P. (Series C) | 31 Dec 2024 | 7,964,000 |
| Farallon Capital Management Llc | 31 Dec 2024 | 6,835,000 |
| Sofinnova Investments, Inc. | 31 Dec 2024 | 5,471,299 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (JMP Securities, 225.50%) | Buy |
| Median | 8.50 (207.41%) | |
| Low | 8.00 (Wells Fargo, 189.33%) | Buy |
| Average | 8.50 (207.41%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 20 Dec 2024 | 8.00 (189.33%) | Buy | 3.23 |
| JMP Securities | 19 Dec 2024 | 9.00 (225.50%) | Buy | 3.23 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |